

European Randomised study of Screening for Prostate Cancer

Submission date 20/12/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 20/12/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 30/10/2025	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mrs M. Roobol

Contact details
Erasmus Medical Center
Department of Urology
P.O. Box 2040
Rotterdam
Netherlands
3000 CA
+31 (0)10 4634548
m.roobol@erasmusmc.nl

Additional identifiers

Protocol serial number
NTR156

Study information

Scientific Title
European Randomised study of Screening for Prostate Cancer

Acronym

ERSPC

Study objectives

Screening causes a difference in prostate cancer mortality of 20% or more.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Local medical ethics committee gave approval

Study design

Multicentre randomised active-controlled parallel-group trial

Primary study design

Interventional

Study type(s)

Screening

Health condition(s) or problem(s) studied

Prostate cancer

Interventions

Prostate Specific Antigen (PSA) determination followed by Digital Rectal Examination (DRE) and prostate biopsy if PSA greater than or equal to 3.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Prostate cancer mortality compared between the screened and the non-screened group of men at risk.

Key secondary outcome(s)

1. Progression-free (tumour free) survival
2. Survival free of metastatic disease
3. Quality of life in the screened and non-screened populations

Completion date

31/12/2010

Eligibility**Key inclusion criteria**

Males aged 55 - 74 years (including age 74)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Senior

Sex

Male

Key exclusion criteria

Previous diagnosis of prostate cancer

Date of first enrolment

01/10/1991

Date of final enrolment

31/12/2010

Locations**Countries of recruitment**

Belgium

Finland

France

Italy

Netherlands

Spain

Sweden

Switzerland

Study participating centre

Erasmus Medical Center

Rotterdam

Netherlands

3000 CA

Sponsor information

Organisation

Erasmus Medical Centre (Netherlands)

ROR

<https://ror.org/018906e22>

Funder(s)

Funder type

Research organisation

Funder Name

The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)

Funder Name

European Union (EU) (Belgium) - Fifth and Sixth Framework Programmes (FP5, FP6)

Funder Name

The National Cancer Fund (Koningin Wilhelmina Fonds [KWF]) (Netherlands)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	26/03/2009		Yes	No
Results article	results	01/08/2011		Yes	No
Results article	results	01/05/2012		Yes	No
	results	01/11			

Results article		/2012		Yes	No
Results article	results	01/02 /2014		Yes	No
Results article	results	01/08 /2015		Yes	No
Results article	European Study of Prostate Cancer Screening - 23- Year Follow-up	30/10 /2025	30/10 /2025	Yes	No
Other publications	11-year follow-up	15/03 /2012		Yes	No
Other publications	13-year follow-up	06/12 /2014		Yes	No
Study website	Study website	11/11 /2025	11/11 /2025	No	Yes